OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Forecast, Price & News $0.36 0.00 (0.00%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.36▼$0.3650-Day Range$0.34▼$0.4352-Week Range$0.28▼$0.53VolumeN/AAverage Volume10,688 shsMarket Capitalization$18.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Antibe Therapeutics (OTCMKTS:ATBPF) StockAntibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATBPF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATBPF Stock News HeadlinesSeptember 8, 2023 | finance.yahoo.comAntibe Announces Results of 2023 Annual MeetingAugust 14, 2023 | finance.yahoo.comAntibe Reports Q1 2024 Interim Financial and Operating ResultsOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>June 29, 2023 | finance.yahoo.comAntibe Reports 2023 Year-End Results and Business HighlightsApril 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)April 6, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)March 12, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATBPF)February 16, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)October 2, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.February 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 9, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)February 7, 2023 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)November 22, 2022 | finance.yahoo.comATBPF: On Track to Initiate Phase 2 Trial for Otenaproxesul in 1H23…October 12, 2022 | finance.yahoo.comAntibe Provides Development Update for OtenaproxesulSeptember 9, 2022 | finance.yahoo.comAntibe Announces Results of 2022 Annual MeetingSeptember 6, 2022 | finance.yahoo.comAntibe Academic Collaborator to Present Clinical Data at PAINWeek 2022July 8, 2022 | finance.yahoo.comATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…July 2, 2022 | finance.yahoo.comWill Antibe Therapeutics (TSE:ATE) Spend Its Cash Wisely?June 30, 2022 | finance.yahoo.comAntibe Therapeutics Reports 2022 Year-End Results and Business HighlightsApril 25, 2022 | nz.finance.yahoo.comAntibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceFebruary 16, 2022 | seekingalpha.comAntibe Therapeutics GAAP EPS of -$0.09February 14, 2022 | finance.yahoo.comAntibe Therapeutics Reports Q3 2022 Interim Financial and Operating ResultsJanuary 28, 2022 | nasdaq.comATBPF Real-Time QuotesDecember 1, 2021 | finance.yahoo.comATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…October 14, 2021 | msn.comBRIEF-Antibe Therapeutics Provides Update On Otenaproxesul And Expanded Drug PipelineOctober 14, 2021 | finance.yahoo.comAntibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug PipelineAugust 19, 2021 | finance.yahoo.comAntibe Therapeutics Announces Results of 2021 Annual MeetingSee More Headlines Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATBPF Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/13/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ATBPF CUSIPN/A CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.80% Return on Assets-27.17% Debt Debt-to-Equity RatioN/A Current Ratio8.57 Quick Ratio8.57 Sales & Book Value Annual Sales$7.67 million Price / Sales2.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.62Miscellaneous Outstanding Shares52,640,000Free Float47,900,000Market Cap$18.86 million OptionableNot Optionable Beta0.36 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 65)L.L.B., Pres, CEO, Sec. & Director Comp: $549.34kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 73)Chief Devel. Officer Comp: $299.94kDr. Joseph Stauffer D.O. (Age 57)M.B.A., Chief Medical Officer Comp: $818.8kDr. Ana StegicExec. Director of Clinical OperationsMs. Christina Cameron B.B.A.VP of Investor RelationsMr. Philip SternVP of CommunicationsMore ExecutivesKey CompetitorsPurple BiotechNASDAQ:PPBTCatalyst BiosciencesNASDAQ:CBIONRx PharmaceuticalsNASDAQ:NRXPAcurx PharmaceuticalsNASDAQ:ACXPAcer TherapeuticsNASDAQ:ACERView All Competitors ATBPF Stock - Frequently Asked Questions Should I buy or sell Antibe Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATBPF shares. View ATBPF analyst ratings or view top-rated stocks. How have ATBPF shares performed in 2023? Antibe Therapeutics' stock was trading at $0.3230 at the beginning of the year. Since then, ATBPF stock has increased by 10.9% and is now trading at $0.3583. View the best growth stocks for 2023 here. Are investors shorting Antibe Therapeutics? Antibe Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 6,900 shares, a decline of 76.4% from the August 31st total of 29,200 shares. Based on an average daily volume of 27,000 shares, the days-to-cover ratio is currently 0.3 days. View Antibe Therapeutics' Short Interest. When is Antibe Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ATBPF earnings forecast. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. What is Antibe Therapeutics' stock symbol? Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPF." How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Antibe Therapeutics' stock price today? One share of ATBPF stock can currently be purchased for approximately $0.36. How much money does Antibe Therapeutics make? Antibe Therapeutics (OTCMKTS:ATBPF) has a market capitalization of $18.86 million and generates $7.67 million in revenue each year. The company earns $-14,730,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. How can I contact Antibe Therapeutics? Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The official website for the company is www.antibethera.com. The company can be reached via phone at (416) 922-3460 or via email at christina@antibethera.com. This page (OTCMKTS:ATBPF) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.